← Leaderboards
Leaf Huang
University Of Pittsburgh At Pittsburgh
$16,174,553
Attributed
$16,174,553
Total exposure
16
Grants
11
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $4.2M · FY2005–19$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
Funding mix
By agency
NIH$32,481,133 · 18
By mechanism
U54$18,220,320 · 5
R01$9,127,086 · 9
P01$4,805,227 · 2
R56$328,500 · 1
P41$0 · 1
Top collaborators
- Joel E Tepper5 shared
Most similar at University Of Pittsburgh At Pittsburgh
Same institution · by research overlap
- Pamela A Moalli$8,505,235
- Mitchell D Creinin$2,236,079
- Feng Liu$1,215,327
- Ruth A Modzelewski$323,816
- Charles A Schreiber$126,149
Others in their field
Top investigators on “Cells”
- Lawrence Corey · Fred Hutchinson Cancer Center$536,344,731
- Barton F Haynes · Duke University$457,457,619
- David Heimbrook · Leidos Biomedical Research, Inc.$454,789,509
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$299,104,942
- Dennis R. Burton · Scripps Research Institute$278,781,854
- Mary M Horowitz · Medical College Of Wisconsin$237,383,608
Research focus
CellsDesignNanoparticleTumorNeoplastic CellLipidsEncapsulatedNanotechnologyLiposomesToxic EffectDoseSmall Interfering RnaMouse ModelGene TherapyMalignant NeoplasmsCancer TherapyPharmaceutical PreparationsSurfaceResponseStructureDrug FormulationsNeoplasm MetastasisNanoLiver
Grant awards (72)
Nano Approaches to Modulate Host Cell Response for Cancer Therapy$2,191,356
U54 · FY2019 · CA · contact PI
Project 1: Nanotherapies for Vemurafenib Resistant Melanoma$445,923
U54 · FY2019 · CA · contact PI
Administrative Core$404,888
U54 · FY2019 · CA · contact PI
Developmental Program$188,277
U54 · FY2019 · CA · contact PI
Nano Approaches to Modulate Host Cell Response for Cancer Therapy$2,261,936
U54 · FY2018 · CA · contact PI
Project 1: Nanotherapies for Vemurafenib Resistant Melanoma$456,006
U54 · FY2018 · CA · contact PI
Administrative Core$414,970
U54 · FY2018 · CA · contact PI
Developmental Program$198,359
U54 · FY2018 · CA · contact PI
Nano Approaches to Modulate Host Cell Response for Cancer Therapy$2,636,624
U54 · FY2017 · CA · contact PI
Project 1: Nanotherapies for Vemurafenib Resistant Melanoma$508,105
U54 · FY2017 · CA · contact PI
Administrative Core$467,068
U54 · FY2017 · CA · contact PI
Hepatic Non-viral Gene Therapy$330,600
R01 · FY2017 · DK · contact PI
Developmental Program$250,457
U54 · FY2017 · CA · contact PI
Nano Approaches to Modulate Host Cell Response for Cancer Therapy$2,512,234
U54 · FY2016 · CA · contact PI
Project 1: Nanotherapies for Vemurafenib Resistant Melanoma$506,470
U54 · FY2016 · CA · contact PI
Administrative Core$460,885
U54 · FY2016 · CA · contact PI
Hepatic Non-viral Gene Therapy$330,600
R01 · FY2016 · DK · contact PI
Developmental Program$220,307
U54 · FY2016 · CA · contact PI
Nano Approaches to Modulate Host Cell Response for Cancer Therapy$2,261,936
U54 · FY2015 · CA · contact PI
Project 1: Nanotherapies for Vemurafenib Resistant Melanoma$456,006
U54 · FY2015 · CA · contact PI
Administrative Core$414,970
U54 · FY2015 · CA · contact PI
Hepatic Non-viral Gene Therapy$330,600
R01 · FY2015 · DK · contact PI
Nanocrystals for the Treatment of Multidrug Resistance in Cancer$307,100
R01 · FY2015 · CA · contact PI
Developmental Program$198,360
U54 · FY2015 · CA · contact PI
Hepatic Non-viral Gene Therapy$330,600
R01 · FY2014 · DK · contact PI
Nanocrystals for the Treatment of Multidrug Resistance in Cancer$297,887
R01 · FY2014 · CA · contact PI
Novel nanoparticles for siRNA delivery$285,192
R01 · FY2014 · CA · contact PI
Therapeutic Targeting of the Ras Pathway By Nanoparticle Delivery of siRNA$149,253
U54 · FY2014 · CA · contact PI
Hepatic Non-viral Gene Therapy$330,600
R01 · FY2013 · DK · contact PI
Novel nanoparticles for siRNA delivery$276,372
R01 · FY2013 · CA · contact PI
Therapeutic Targeting of the Ras Pathway By Nanoparticle Delivery of siRNA$144,322
U54 · FY2013 · CA · contact PI
LPD Nanoparticles in Anti-Cancer Therapy$292,520
R01 · FY2012 · CA · contact PI
Interaction of cationic lipids with dendritic cells$292,148
R01 · FY2012 · CA · contact PI
Novel nanoparticles for siRNA delivery$238,594
R01 · FY2012 · CA · contact PI
Therapeutic Targeting of the Ras Pathway By Nanoparticle Delivery of siRNA$155,600
U54 · FY2012 · CA · contact PI
LPD Nanoparticles in Anti-Cancer Therapy$292,676
R01 · FY2011 · CA · contact PI
Interaction of cationic lipids with dendritic cells$292,197
R01 · FY2011 · CA · contact PI
Novel nanoparticles for siRNA delivery$238,594
R01 · FY2011 · CA · contact PI
Therapeutic Targeting of the Ras Pathway By Nanoparticle Delivery of siRNA$155,599
U54 · FY2011 · CA · contact PI
LPD Nanoparticles in Anti-Cancer Therapy$301,885
R01 · FY2010 · CA · contact PI
Interaction of cationic lipids with dendritic cells$301,284
R01 · FY2010 · CA · contact PI
Novel nanoparticles for siRNA delivery$245,973
R01 · FY2010 · CA · contact PI
Therapeutic Targeting of the Ras Pathway By Nanoparticle Delivery of siRNA$160,409
U54 · FY2010 · CA · contact PI
LPD Nanoparticles in Anti-Cancer Therapy$301,708
R01 · FY2009 · CA · contact PI
Interaction of cationic lipids with dendritic cells$301,333
R01 · FY2009 · CA · contact PI
Interaction of cationic lipids with dendritic cells$301,380
R01 · FY2008 · CA · contact PI
LPD Nanoparticles in Anti-Cancer Therapy$300,211
R01 · FY2008 · CA · contact PI
Safe and Efficacious Non-viral Vectors for Gene Therapy$328,500
R56 · FY2007 · AI · contact PI
Advance Drug Delivery for Bladder Dysfunction$250,476
R01 · FY2007 · DK · contact PI
Advance Drug Delivery for Bladder Dysfunction$258,105
R01 · FY2006 · DK · contact PI
Advance Drug Delivery for Bladder Dysfunction$236,627
R01 · FY2005 · DK
INFLAMMATORY TOXICITY IN NON-VIRAL GENE THERAPY$208,758
R01 · FY2005 · AI
Advance Drug Delivery for Bladder Dysfunction$32,182
R01 · FY2005 · DK
INFLAMMATORY TOXICITY IN NON-VIRAL GENE THERAPY$12,854
R01 · FY2005 · AI
Advance Drug Delivery for Bladder Dysfunction$269,395
R01 · FY2004 · DK
INFLAMMATORY TOXICITY IN NON-VIRAL GENE THERAPY$221,613
R01 · FY2004 · AI
IMPROVING MUSCLE FUNCTION THROUGH GENE DELIVERY$1,153,364
P01 · FY2003 · AR
INFLAMMATORY TOXICITY IN NON-VIRAL GENE THERAPY$221,613
R01 · FY2003 · AI
IMPROVING MUSCLE FUNCTION THROUGH GENE DELIVERY$1,122,105
P01 · FY2002 · AR
INFLAMMATORY TOXICITY IN NON-VIRAL GENE THERAPY$220,347
R01 · FY2002 · AI
HBV /CHYLOMICRON HYBRID VECTOR FOR LIVER GENE TRANSFER$103,677
P01 · FY2002 · DK
LIPOSOME MEDIATED GENE THERAPY$0
P41 · FY2002 · RR
LIPOSOME MEDIATED GENE THERAPY$0
P41 · FY2002 · RR
IMPROVING MUSCLE FUNCTION THROUGH GENE DELIVERY$1,092,657
P01 · FY2001 · AR
INFLAMMATORY TOXICITY IN NON-VIRAL GENE THERAPY$219,081
R01 · FY2001 · AI
GENE THERAPY FOR CERVICAL CARCINOMA$181,235
R01 · FY2001 · CA
HBV /CHYLOMICRON HYBRID VECTOR FOR LIVER GENE TRANSFER$103,677
P01 · FY2001 · DK
LIPOSOME MEDIATED GENE THERAPY$0
P41 · FY2001 · RR
IMPROVING MUSCLE FUNCTION THROUGH GENE DELIVERY$1,074,368
P01 · FY2000 · AR
GENE THERAPY FOR CERVICAL CARCINOMA$175,956
R01 · FY2000 · CA
HBV /CHYLOMICRON HYBRID VECTOR FOR LIVER GENE TRANSFER$155,379
P01 · FY2000 · DK
LIVER SPECIFIC NONVIRAL VECTORS$98,790
R01 · FY2000 · DK